Bibliography
- NEWCOMBE DS: Leukotrienes. In: Principals of Medical Biolology. Bittar EE, Bittar N (Eds.), JAI Press, Greenwich, CT (1997) 8B:655–686.
- SPECTOR S: Leukotriene activity modulation in asthma. Drugs (1997) 54 (3) :369–384.
- •A good overview of clinical results with the LTD4 antago-nists zafirlukast, pranlukast and montelukast.
- CROOKS SW, STOCKLEY RA: Leukotriene 134. Int. J. Bio-chem. Cell Biol. (1998) 30:173–178.
- SAWYER JS: Leukotriene 134 receptor antagonists: re-cent clinical developments. Exp. Opin. Invest. Drugs (1996) 5(0:73–77.
- •Although somewhat dated, this is perhaps the best review of LTB4 antagonists in the clinic.
- NAKAYAMA Y, SENOKUCHI K, NAKAI H et al.: Therapeutic potential of trypsin-like serine protease inhibitors. Drugs Future (1997) 22 (3) :285–293.
- •A good introduction to dual serine protease inhibitors/LTB4 antagonists highlighting ONO–3403.
- KATORI M, NISHIYAMA K, IGUCHI Y et al.: Reduction by a killikrein inhibitor of the increased nasal airway re-sistance of allergic patients after antigen challenge. Immunopharmacology (1996) 33:308–310.
- EVANS DJ, BARNES PJ, SPAETHE SM et al.: Effect of a leu-kotriene 134 receptor antagonist, LY 293111, on aller-gen induced responses in asthma. Thorax (1996) 51(12):1178–1184.
- HELLER A, KOCH T, SCHMECK J et al.: Lipid mediators in inflammatory disorders. Drugs (1998) 55(4) :487–496.
- AGGARWAL ND, GOLDMAN D, MALICK AW et al.: Degra-dation profile and reverse-phase LC method develop-ment of the antiinflammatory drug, Ro 24-5913. J. Pharm. Biomed. Anal. (1993) 11 (10) :1037–1043.
- DEVILLIER P, BESSARD G : Thromboxane Ay and related prostaglandins in airways. Fund. Clin. Pharmacol. (1997) 11:2–18.
- MIZUSHIMA Y, OOSAKI R: Clinical potential of anti-thromboxane Ay agents in bronchial asthma. BioDrugs (1997) 7(2):91–98.
- CORNE JM, HOLGATE ST et al.: Hi-receptor antagonists in asthma. Clin. Allergy Immunol. (1996) 7:251–271.
- MENARDO JL, HORAK F, DANZIG MR et al.: A review of lo-ratadine in the treatment of patients with allergic bronchial asthma. Clin. Ther. (1997) 19(6) :1278–1293.
- SAKURAI S, OGAWA N, ONOGI Y et al.: Synthesis and dual antagonist activity against thromboxane A2 and leukotriene D4 of [441 - (benzenesulfonamido) al-kyllphenylialkanoic acid derivatives. Chem. Pharm. Bull. (1997) 45(5):849–862.
- ••This paper describes a series of analogues which demon-strate additive dual LTD4/TXA2 antagonist activity.
- ZHANG MQ, VAN DE STOLPE A, ZUIDERVELD et al.: Synthesis and pharmacological evaluation of some amino acid containing cyproheptadine derivatives as dual antagonists of histamine Hi and leukotriene D4 receptors. Eur. J. Med. Chem. (1997) 32:95–102.
- ••This article describes a series of analogues which demon-strate synergistic dual histamine Hi/LTD4 antagonist activity.
- HAWKEY CJ, DUBE LM, ROUNTREE LV et al.: A trial of zileuton versus mesalazine or placebo in the mainte-nance of remission of ulcerative colitis. Gastroenterol-ogy (1997) 112(3):718–724.
- WEINBLATT ME, KREMER JM, COBLYN JS et al.: Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J. Rheumatol. (1992) 19(101537–1541.
- IN KH, ASANO K, BEIER D et al.:Naturally occurring mu-tations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. (1997) 99 (5) :1130–1137.
- SENDA S, FUJIYAMA Y, BAMBA T et al.: Treatment of ul-cerative colitis with camostat mesilate, a serine prote-ase inhibitor. Int. Med. (1993) 32 (0350–354.